JP2011524890A - １を超える活性医薬成分の部位特異的デリバリーのための医薬剤形 - Google Patents
１を超える活性医薬成分の部位特異的デリバリーのための医薬剤形 Download PDFInfo
- Publication number
- JP2011524890A JP2011524890A JP2011514138A JP2011514138A JP2011524890A JP 2011524890 A JP2011524890 A JP 2011524890A JP 2011514138 A JP2011514138 A JP 2011514138A JP 2011514138 A JP2011514138 A JP 2011514138A JP 2011524890 A JP2011524890 A JP 2011524890A
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- pharmaceutical dosage
- polymer
- api
- platform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 145
- 239000008186 active pharmaceutical agent Substances 0.000 title claims abstract description 95
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 33
- 229920000642 polymer Polymers 0.000 claims abstract description 157
- 210000002784 stomach Anatomy 0.000 claims abstract description 33
- 238000010521 absorption reaction Methods 0.000 claims abstract description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 229920001661 Chitosan Polymers 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 44
- 239000001814 pectin Substances 0.000 claims description 39
- 229920001277 pectin Polymers 0.000 claims description 39
- 235000010987 pectin Nutrition 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 31
- 239000008187 granular material Substances 0.000 claims description 29
- 229940111202 pepsin Drugs 0.000 claims description 29
- 108090000284 Pepsin A Proteins 0.000 claims description 28
- 102000057297 Pepsin A Human genes 0.000 claims description 27
- 238000000576 coating method Methods 0.000 claims description 27
- 230000002496 gastric effect Effects 0.000 claims description 25
- 150000004676 glycans Chemical class 0.000 claims description 23
- 229920001282 polysaccharide Polymers 0.000 claims description 23
- 239000005017 polysaccharide Substances 0.000 claims description 23
- 210000001072 colon Anatomy 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 20
- 238000011065 in-situ storage Methods 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000004971 Cross linker Substances 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 229940088598 enzyme Drugs 0.000 claims description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 12
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 229920001059 synthetic polymer Polymers 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 10
- 210000000813 small intestine Anatomy 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 238000007907 direct compression Methods 0.000 claims description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims description 8
- 230000030136 gastric emptying Effects 0.000 claims description 8
- 229920000126 latex Polymers 0.000 claims description 8
- 229920005615 natural polymer Polymers 0.000 claims description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005550 wet granulation Methods 0.000 claims description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 7
- 229940072056 alginate Drugs 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000004816 latex Substances 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 230000000112 colonic effect Effects 0.000 claims description 5
- 210000004051 gastric juice Anatomy 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 230000004043 responsiveness Effects 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 238000007908 dry granulation Methods 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- -1 opioid Substances 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 230000002028 premature Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 210000001187 pylorus Anatomy 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 230000036962 time dependent Effects 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 108010059820 Polygalacturonase Proteins 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000000078 anti-malarial effect Effects 0.000 claims description 2
- 230000000798 anti-retroviral effect Effects 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 238000010382 chemical cross-linking Methods 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 230000002183 duodenal effect Effects 0.000 claims description 2
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 2
- 210000003736 gastrointestinal content Anatomy 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000002086 nanomaterial Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 230000002522 swelling effect Effects 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000008014 pharmaceutical binder Substances 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 112
- 239000003814 drug Substances 0.000 description 112
- 238000012377 drug delivery Methods 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 6
- 229920003139 Eudragit® L 100 Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 6
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 6
- 229960001763 zinc sulfate Drugs 0.000 description 6
- 229910000368 zinc sulfate Inorganic materials 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920003141 Eudragit® S 100 Polymers 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003517 fume Substances 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 229940063656 aluminum chloride Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 229940045511 barium chloride Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940040387 citrus pectin Drugs 0.000 description 2
- 239000009194 citrus pectin Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102100039652 Pepsin A-5 Human genes 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 1
- 229940009861 aluminum chloride hexahydrate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124537 antidiarrhoeal agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- PWHCIQQGOQTFAE-UHFFFAOYSA-L barium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ba+2] PWHCIQQGOQTFAE-UHFFFAOYSA-L 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical group C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940066716 pepsin a Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2007/11000 | 2008-06-19 | ||
| ZA200711000 | 2008-06-19 | ||
| PCT/IB2009/005830 WO2009153633A1 (en) | 2008-06-19 | 2009-06-03 | Pharmaceutical dosage form for the site-specific delivery of more than one active pharmaceutical ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011524890A true JP2011524890A (ja) | 2011-09-08 |
| JP2011524890A5 JP2011524890A5 (enExample) | 2012-07-19 |
Family
ID=41116789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514138A Pending JP2011524890A (ja) | 2008-06-19 | 2009-06-03 | １を超える活性医薬成分の部位特異的デリバリーのための医薬剤形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110182987A1 (enExample) |
| EP (1) | EP2306984A1 (enExample) |
| JP (1) | JP2011524890A (enExample) |
| WO (1) | WO2009153633A1 (enExample) |
| ZA (1) | ZA200903858B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018518520A (ja) * | 2015-06-26 | 2018-07-12 | ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルクＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｈｅ Ｗｉｔｗａｔｅｒｓｒａｎｄ， Ｊｏｈａｎｎｅｓｂｕｒｇ | ペプチドおよび／またはタンパク質の送達のための経口医薬投与形態 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9808418B2 (en) | 2010-11-26 | 2017-11-07 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
| WO2014043084A1 (en) * | 2012-09-11 | 2014-03-20 | University Of Massachusetts | Polymer-polymer composite nanoassemblies and applications thereof |
| FR2997605B1 (fr) * | 2012-11-08 | 2015-12-11 | Rhodia Operations | Suspensions aqueuses pour compositions agricoles |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015186108A1 (en) * | 2014-06-05 | 2015-12-10 | University Of The Witwatersrand, Johannesburg | 2 layers tablet oral dosage form for various drug release |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3610862A1 (en) * | 2018-08-14 | 2020-02-19 | Apillet APS | Novel oral composition |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05508156A (ja) * | 1990-07-04 | 1993-11-18 | カビ・フアーマシア・アクチエボラーグ | 治療用組成物及びその製造方法 |
| JP2000256216A (ja) * | 1999-03-04 | 2000-09-19 | Meiji Milk Prod Co Ltd | ゲル組成物 |
| JP2001525848A (ja) * | 1997-05-24 | 2001-12-11 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | 改良ドラッグデリバリーのための胃保持型（ｇａｓｔｒｏｒｅｔｅｎｔｉｖｅ）制御放出微小球体（Ｍｉｃｒｏｓｐｈｅｒｅｓ） |
| JP2004513182A (ja) * | 2000-06-07 | 2004-04-30 | ツアン、ハオ | 特異的結腸送達用経口製剤およびその製造法 |
| JP2005325081A (ja) * | 2004-05-17 | 2005-11-24 | Medorekkusu:Kk | 経口腸溶性製剤 |
| JP2007517939A (ja) * | 2004-01-06 | 2007-07-05 | ユニヴェルシテ・ドゥ・シャーブルック | キトサンをその酸性溶液から回収するための簡易法 |
| WO2008062440A2 (en) * | 2006-09-04 | 2008-05-29 | Panacea Biotec Limited | Programmable buoyant delivery technology |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4994570B2 (ja) * | 2001-07-04 | 2012-08-08 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | 胃保持制御ドラッグデリバリーシステム |
| US7157100B2 (en) * | 2002-06-04 | 2007-01-02 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
| CN101128187A (zh) * | 2005-02-09 | 2008-02-20 | 达沃尔泰拉公司 | 活性剂的结肠递送 |
| US20080268045A1 (en) * | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
-
2009
- 2009-06-01 ZA ZA2009/03858A patent/ZA200903858B/en unknown
- 2009-06-03 JP JP2011514138A patent/JP2011524890A/ja active Pending
- 2009-06-03 WO PCT/IB2009/005830 patent/WO2009153633A1/en not_active Ceased
- 2009-06-03 EP EP09766175A patent/EP2306984A1/en not_active Ceased
- 2009-06-03 US US12/999,824 patent/US20110182987A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05508156A (ja) * | 1990-07-04 | 1993-11-18 | カビ・フアーマシア・アクチエボラーグ | 治療用組成物及びその製造方法 |
| JP2001525848A (ja) * | 1997-05-24 | 2001-12-11 | ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド | 改良ドラッグデリバリーのための胃保持型（ｇａｓｔｒｏｒｅｔｅｎｔｉｖｅ）制御放出微小球体（Ｍｉｃｒｏｓｐｈｅｒｅｓ） |
| JP2000256216A (ja) * | 1999-03-04 | 2000-09-19 | Meiji Milk Prod Co Ltd | ゲル組成物 |
| JP2004513182A (ja) * | 2000-06-07 | 2004-04-30 | ツアン、ハオ | 特異的結腸送達用経口製剤およびその製造法 |
| JP2007517939A (ja) * | 2004-01-06 | 2007-07-05 | ユニヴェルシテ・ドゥ・シャーブルック | キトサンをその酸性溶液から回収するための簡易法 |
| JP2005325081A (ja) * | 2004-05-17 | 2005-11-24 | Medorekkusu:Kk | 経口腸溶性製剤 |
| WO2008062440A2 (en) * | 2006-09-04 | 2008-05-29 | Panacea Biotec Limited | Programmable buoyant delivery technology |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018518520A (ja) * | 2015-06-26 | 2018-07-12 | ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルクＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｈｅ Ｗｉｔｗａｔｅｒｓｒａｎｄ， Ｊｏｈａｎｎｅｓｂｕｒｇ | ペプチドおよび／またはタンパク質の送達のための経口医薬投与形態 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200903858B (en) | 2013-10-30 |
| EP2306984A1 (en) | 2011-04-13 |
| WO2009153633A1 (en) | 2009-12-23 |
| US20110182987A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524890A (ja) | １を超える活性医薬成分の部位特異的デリバリーのための医薬剤形 | |
| Streubel et al. | Gastroretentive drug delivery systems | |
| RU2093148C1 (ru) | Композиции с замедленным (пролонгированным) высвобождением | |
| JP2001519379A (ja) | 遅延性総放出胃腸薬物送達システム | |
| JP2000503316A (ja) | 胃腸の薬物送達システム | |
| AU2005334837B2 (en) | PH-controlled pulsatile delivery system, methods for preparation and use thereof | |
| US20240082168A1 (en) | Controlled drug release formulation | |
| KR20220019021A (ko) | 물-활성화된 점막부착성 조성물, 및 생물학적 활성 성분을 전달하는 방법 | |
| Scholtz et al. | More good news about polymeric plant-and algae-derived biomaterials in drug delivery systems | |
| Kumari et al. | An update overview of recent advances on formulation development for colon targeting | |
| Vibhooti et al. | Eudragit and chitosan—The two most promising polymers for colon drug delivery | |
| Fish et al. | Drug delivery to the colon | |
| Shah et al. | DEVELOPMENTS IN COLON SPECIFIC DRUG DELIVERY SYSTEMS-A REVIEW. | |
| WO2020011938A1 (en) | Glucocorticoids for the topical treatment of autoimmune gastritis | |
| Xi | QBD Approach for Development of Ivermectin-Loaded Gastro Retentive Sustained Release Tablets as Mass Drug Administration for Malaria Transmission Control | |
| Liu | Update on polymers for oral drug delivery | |
| Kaur et al. | Recent approaches for colon drug delivery | |
| JP6454630B2 (ja) | ｐＨ制御パルス送達システム、その調製法及び使用法 | |
| Surti et al. | Colonic drug delivery systems as multiunit potential: therapeutic strategies and opportunities | |
| Sharma et al. | Various Approaches Used For Colonic Drug Delivery System | |
| Swain et al. | Recent advances in colon-specific drug delivery systems | |
| WO2025078629A1 (en) | Capsule for delivery of a carrier system with a locally acting cargo to the intestines of a mammal | |
| Gowri | Different Methods of Formulation and Evaluation of Mucoadhesive Microspheres by using Various Polymers for H2 Receptor Antagonist Drug | |
| Ferrari et al. | Colonic Drug Delivery: Biopolymers and Enteric Polymers | |
| FR2830446A1 (fr) | Composition pharmaceutique destinee a liberer une substance active au niveau du colon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120601 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120601 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131018 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20131219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140106 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140411 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140722 |